$56,730.94 ownership Payment -- Amgen Inc to Dr. Paul Turner

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Amgen Inc made a $56.7K ownership payment to Paul Turner, a Cardiology specialist in Athens, GA. This record details a significant ownership or investment interest valued at $56,730.94. The payment was made by Amgen Inc. to Dr. Paul Turner, a cardiologist in Athens, GA. The transaction occurred on January 6, 2026, and is categorized as an ownership/investment interest.

Patient Guidance: What This Payment Means for You

This record shows a financial relationship where a doctor has an ownership stake in a pharmaceutical company. It's important to understand how these relationships might influence medical advice. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interests in pharmaceutical companies are common across many specialties, but the size of this investment may warrant further review within cardiology.

Regulatory Context: Sunshine Act Requirements

This disclosure is mandated under the Physician Payments Sunshine Act, part of the Affordable Care Act, requiring transparency in financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• amgen-inc
• cardiology
• physician-payment
• investment
• cms-open-payments

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $56.7K payment for?

This was a ownership payment of $56.7K from Amgen Inc to Paul Turner, categorized as "Ownership or Investment Interest". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Paul Turner accept pharmaceutical money?

Yes, Paul Turner received this $56.7K payment from Amgen Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Paul Turner's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $56.7K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Cardiology?

To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Paul Turner's relationship with Amgen Inc?

The payment amount is substantial, indicating a potentially significant financial relationship. This $56.7K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Cardiology?

The payment type is 'ownership', suggesting a direct financial stake rather than a service payment.

What should patients do after learning about this payment?

This record shows a financial relationship where a doctor has an ownership stake in a pharmaceutical company. It's important to understand how these relationships might influence medical advice.

What else should I know about this ownership payment?

The specialty 'Cardiology' is noted, which may be relevant given the prevalence of cardiovascular drugs.

Related Reports

• View Dr. Paul Turner's full payment report
• Amgen Inc full spending report
• Browse all Cardiology payments
• Browse all payments in Georgia
• Search for other payments